CLAIMS

1. A compound of formula (I), or a pharmaceutically acceptable salt thereof:



(**I**)

wherein

R^1 is independently at each occurrence selected from: C_1-C_{24}-alkyl, C_3-C_{24}-alkenyl, C_3-C_{24}-alkynyl, C_0-C_4-alkylene-C_3-C_8-cycloalkyl and C_0-C_4-alkylene-aryl;

R^2 and R^3 are each independently at each occurrence selected from H, C_1-C_6-alkyl and C_1-C_3-alkylene-R^7; or R^2 and R^3 together with the atom to which they are attached form a 3- to 6-membered cycloalkyl or heterocycloalkyl group;

R^4 is independently at each occurrence H or C_1-C_4-alkyl;

or R^4, a group selected from R^2 and R^3 and the atoms to which they are attached may form a 3- to 6-membered heterocycloalkyl group;

R^5 is independently at each occurrence selected from aryl, 5-, 6-, 9- or 10-membered heteroaryl, C_3-C_8-cycloalkyl, 3- to 7-membered heterocycloalkyl, C_1-C_3-alkylene-R^{5a} and C_1-C_8-alkyl, said aryl being optionally fused to C_6-C_8-cycloalkyl;

R^{5a} is independently at each occurrence selected from aryl, 5-, 6-, 9- or 10-membered heteroaryl, C_3-C_8-cycloalkyl, 3- to 7-membered heterocycloalkyl, said aryl being optionally fused to C_6-C_8-cycloalkyl;

R^6 is independently selected from:









and ;

R^7 is independently at each occurrence selected from aryl, imidazole, indole, SR^a, OR^a, CO_2R^a, $CO_2NR^aR^a$, NR^aR^b and $NH(=NH)NH_2$;

R^8 is independently selected from H and



;

Z^1 and Z^2 are each independently selected from O and S;

Y is independently selected from H, F, Cl and OMe;

X is independently at each occurrence a pharmaceutically acceptable cation;

wherein any aryl group is either phenyl or naphthyl;

wherein where any of R^1, R^2, R^3, R^4, R^5 or R^7 is an alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, that alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl group is optionally substituted with from 1 to 4 substituents selected from: halo, nitro, cyano, NR^aR^a, $NR^aS(O)_2R^a$, $NR^aC(O)R^a$, $NR^aCONR^aR^a$, $NR^aCO_2R^a$, OR^a; SR^a, SOR^a, SO_3R^a, SO_2R^a, $SO_2NR^aR^a$, CO_2R^a $C(O)R^a$, $CONR^aR^a$, $CR^aR^aNR^aR^a$, C_1-C_4-alkyl, C_2-C_4-alkenyl, C_2-C_4-alkynyl and C_1-C_4-haloalkyl;

wherein R^a is independently at each occurrence selected from: H and C_1-C_4-alkyl; and R^b is independently at each occurrence selected from: H, and C_1-C_4-alkyl and C(O)-C_1-C_4-alkyl.

2. A compound of claim 1, wherein R^4 is H.

3. A compound of claim 1 or claim 2, wherein R^6 is



.

4. A compound of claim 1 or claim 2, wherein R^6 is



; or

wherein R^6 is



; or

wherein R^6 is



; or

wherein R^6 is



; or

wherein R^6 is



; or

wherein R^6 is



.

5. A compound of any one of claims 1 to 4, wherein R^1 is selected from C_5-C_7-cycloalkyl, C_1-C_8-alkyl and benzyl.

6. A compound of claim 5, wherein R^1 is benzyl.

7. A compound of claim 5, wherein R^1 is C_1-C_8-alkyl, e.g. ethyl.

8. A compound of any one of claims 1 to 7, wherein R^3 is H.

9. A compound of any one of claims 1 to 8, wherein R^2 is C_1-C_4-alkyl.

10. A compound of any one of claims 1 to 8, wherein R^2 is H.

11. A compound of any one of claims 1 to 10, wherein R^5 is phenyl.

12. A compound of any one of claims 1 to 10, wherein R^5 is naphthyl.

13. A compound of claim 1, wherein the compound of formula (I) is selected from:



,



,


H2N
N
N
Cl
N
N
O
O
PhO
P
O
P
O
O
O
NH
O-X+
Ph
O
O
F
OH

,


O
F
NH
O
NpO
P
O
P
O
O
N
O
NH
O-X+
Ph
O
O
Me
OH

,


NH2
N
O
PhO
P
O
P
O
O
N
O
NH
O-X+
Ph
O
O
F
Me
OH
F

,


H2N
N
N
Cl
N
N
O
NpO
P
O
P
O
O
NH
O-X+
Ph
O
O
Me
OH
OH

,





,



,



,


H2N
N
N
Cl
N
N
O
O
O
NpO
P
O
P
O
O
NH
O-X+
Ph
O
O
F
OH

,


H2N
N
N
Cl
N
N
O
O
O
PhO
P
O
P
O
O
NH
O-X+
O
O
F
OH

,


H2N
N
N
Cl
N
N
O
O
O
NpO
P
O
P
O
O
NH
O-X+
O
O
F
OH

,


H2N
N
N
Cl
N
N
O
O
O
PhO
P
O
P
O
O
NH
O-X+
O
O
F
OH

,


H2N
N
N
Cl
N
N
O
O
O
PhO
P
O
P
O
O
NH
O-X+
O
O
F
OH

5 ,



,



,



,



,



,



,



,



,



,



and



.

14. A compound of any one of claims 1 to 13 wherein X^+ is a metal cation or an ammonium cation.

15. A compound of any one of claims 1 to 14 for use in treatment.

16. A compound of any one of claims 1 to 14 for use in treating cancer; optionally

wherein the cancer is leukaemia or lymphoma; further optionally

wherein the cancer is a leukaemia selected from the group consisting of acute myeloid leukaemia (AML), acute lymphoid leukaemia (ALL), chronic myeloid leukaemia (CML), chronic lymphoid leukaemia (CLL) and biphenotypic acute leukaemia (BAL); or

wherein the cancer is a lymphoma selected from the group consisting of Hodgkin's lymphoma and non-Hodgkin's lymphoma.

17. A pharmaceutical composition comprising compounds of any one of claims 1 to 14 and at least one pharmaceutically acceptable excipient.